Published online by Cambridge University Press: 10 October 2020
Uterine fibroids are the most common benign tumour in premenopausal women, with a lifetime prevalence of almost 70% in Caucasian women and more than 80% in women of Afro-Caribbean descent. About half of these women experience symptoms, with the most common being menorrhagia, dysmenorrhoea, pressure symptoms and infertility. Whilst hysterectomy is still the most commonly offered and performed operation to treat uterine fibroids, over the last 20 years minimally invasive therapies have been gaining popularity and uterine fibroid embolization is now a mainstream option for most women who wish to preserve their uterus. Since its introduction, a strong body of evidence has built demonstrating safety and efficacy with low rates of complication. Uterine fibroid embolization (UFE) was first described as a treatment for symptomatic leiomyomas in 1995 by Ravina et al. and has proved so popular that in the last year there were over 25,000 uterine fibroid embolization procedures performed worldwide .